Nankai Hecheng (南开和成) develops ion‑exchange resin products including medicinal adsorption resins, solid‑phase synthesis carrier resins, immobilized enzyme resins, hemoperfusion resins, ion‑exchange resins, and chromatographic separation resins. Its products are used in solid‑phase synthesis of peptide and DNA drugs, separation and purification of peptides and proteins, semi‑synthesis of antibiotic drugs, and purification of natural products from traditional Chinese medicine. Other application areas include hemoperfusion, the food industry, water treatment, and hydrometallurgy. The company sells its products domestically and internationally. Recently Nankai Hecheng completed a ¥10 million Series A financing. The disclosed investor in the round was Bohai Chuangfu (渤海创富), according to IT Juzi.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024